Compare MCB & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | CADL |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2021 |
| Metric | MCB | CADL |
|---|---|---|
| Price | $87.50 | $9.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $105.33 | $21.75 |
| AVG Volume (30 Days) | 99.7K | ★ 1.1M |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | 11.64 | ★ 58.62 |
| EPS | ★ 4.40 | N/A |
| Revenue | ★ $11,053,000.00 | $125,000.00 |
| Revenue This Year | $20.34 | N/A |
| Revenue Next Year | $13.88 | N/A |
| P/E Ratio | $20.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $64.66 | $4.35 |
| 52 Week High | $102.04 | $14.00 |
| Indicator | MCB | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 35.54 |
| Support Level | $86.55 | $9.18 |
| Resistance Level | $93.55 | $10.59 |
| Average True Range (ATR) | 1.86 | 0.65 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 32.17 | 7.48 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.